BRCA Mutations and Breast Cancer Prevention
Round 1
Reviewer 1 Report
1)actual numbers re ovarian cancer risk from multiple studies would give 12&rate not 21%
2)same for breast risk with ranges
3) hypothesis as to why estrogen bad in face of ER negativity
4)why has literature changed re risk reduction from oophorectomy to instead a survival benefit-what was the methodologic bias that was operational
5)is the survival benefit post oophorectomy re breast cancer specific survival or is purely overall*
6) what does the author recommend to practitioners re age at mastectomy and specifically any age group who should not have it
7)tamoxifen preventing second breast cancer but not the initial does not make intuitive sense-please discuss further
8)aspirin and metformin have also been put forward as chemo prevention- any datA in BRCA
9) does the suthor believe that if the data pans out that deosumab type drugs would be used as chemoprevention
10)last paragraph in summary not add anything to paper
110\0 need paragraph on screening to be all inclusiver
Author Response
Please see attached file.
Author Response File: 
Author Response.pdf
Reviewer 2 Report
Please see attached file.
Comments for author File: Comments.pdf
Author Response
See the attached file
Author Response File: Author Response.pdf
Round 2
Reviewer 1 Report
acceptable for publication with proof reading for spelling errors and missed words
Reviewer 2 Report
The authors have address my comments from prior review satisfactorily.
